These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 35754979)

  • 1. Patients' Perspectives on Coming Off Opioid Agonist Treatment: A Qualitative Study.
    Nehlin C; Bäckström J; Brander CW; Öster C
    Subst Abuse; 2022; 16():11782218221107021. PubMed ID: 35754979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Caregivers' Attitudes Toward Treatment Length for Persons in Swedish Opioid Agonist Treatment. A Qualitative Interview Study.
    Nehlin C; Brander CW; Öster C
    J Psychoactive Drugs; 2024; 56(3):373-379. PubMed ID: 37353937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged-release opioid agonist therapy: qualitative study exploring patients' views of 1-week, 1-month, and 6-month buprenorphine formulations.
    Neale J; Tompkins CNE; Strang J
    Harm Reduct J; 2019 Apr; 16(1):25. PubMed ID: 30943990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Accessibility of Opioid Agonist Treatment and Its Forced Discontinuation in Swiss Prisons-Attitudes, Perceptions and Experiences of Defense Lawyers in Dealing With Detained Persons Using Opioids.
    Buadze A; Baggio S; Schleifer R; Aeberhard E; Wolff H; Schneeberger A; Liebrenz M
    Front Psychiatry; 2020; 11():395. PubMed ID: 32477183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methadone and buprenorphine treatment in United States jails and prisons: lessons from early adopters.
    Bandara S; Kennedy-Hendricks A; Merritt S; Barry CL; Saloner B
    Addiction; 2021 Dec; 116(12):3473-3481. PubMed ID: 33999458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study.
    Russell C; Nafeh F; Pang M; MacDonald SF; Derkzen D; Rehm J; Fischer B
    BMC Public Health; 2022 Mar; 22(1):436. PubMed ID: 35246083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mal/adaptations: A qualitative evidence synthesis of opioid agonist therapy during major disruptions.
    Salamanca-Buentello F; Cheng DK; Sabioni P; Majid U; Upshur R; Sud A
    Int J Drug Policy; 2022 Mar; 101():103556. PubMed ID: 34902805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What features of drug treatment programs help, or not, with access? a qualitative study of the perspectives of family members and community-based organization staff in Atlantic Canada.
    Mathias H; Jackson LA; Buxton JA; Dubé A; Kiepek N; Martin F; Martin P
    Subst Abuse Treat Prev Policy; 2024 Mar; 19(1):20. PubMed ID: 38520017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study.
    Pearce LA; Min JE; Piske M; Zhou H; Homayra F; Slaunwhite A; Irvine M; McGowan G; Nosyk B
    BMJ; 2020 Mar; 368():m772. PubMed ID: 32234712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opioid agonist therapy trajectories among street entrenched youth in the context of a public health crisis.
    Giang V; Thulien M; McNeil R; Sedgemore K; Anderson H; Fast D
    SSM Popul Health; 2020 Aug; 11():100609. PubMed ID: 32613075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A qualitative systematic review of internal and external influences on shared decision-making in all health care settings.
    Truglio-Londrigan M; Slyer JT; Singleton JK; Worral P
    JBI Libr Syst Rev; 2012; 10(58):4633-4646. PubMed ID: 27820528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physician prescribing of opioid agonist treatments in provincial correctional facilities in Ontario, Canada: A survey.
    Kouyoumdjian FG; Patel A; To MJ; Kiefer L; Regenstreif L
    PLoS One; 2018; 13(2):e0192431. PubMed ID: 29447177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions.
    Bouck Z; Scheim AI; Gomes T; Ling V; Caudarella A; Werb D
    Int J Drug Policy; 2022 Jun; 104():103680. PubMed ID: 35447476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preferences and decisional considerations relating to opioid agonist therapy among Ukrainian people who use drugs: A conjoint analysis survey.
    Bromberg DJ; Madden LM; Fraenkel L; Muthulingam D; Rhoades D; Dvoriak S; Dumchev K; Pykalo I; Altice FL
    PLOS Glob Public Health; 2024; 4(1):e0002725. PubMed ID: 38277422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Publicly Funded Treatment of Opioid Use Disorder in California.
    Krebs E; Enns B; Evans E; Urada D; Anglin MD; Rawson RA; Hser YI; Nosyk B
    Ann Intern Med; 2018 Jan; 168(1):10-19. PubMed ID: 29159398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilization of opioid agonist therapy among incarcerated persons with opioid use disorder in Vancouver, Canada.
    Bozinoff N; DeBeck K; Milloy MJ; Nosova E; Fairbairn N; Wood E; Hayashi K
    Drug Alcohol Depend; 2018 Dec; 193():42-47. PubMed ID: 30340144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. State criminal justice policy context and opioid agonist treatment delivery among opioid treatment admissions, 2015.
    Mantha S; Mauro PM; Mauro CM; Martins SS
    Drug Alcohol Depend; 2020 Jan; 206():107654. PubMed ID: 31735533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid Agonist Treatment Recipients within Criminal Justice-Involved Populations.
    Guastaferro WP; Koetzle D; Lutgen-Nieves L; Teasdale B
    Subst Use Misuse; 2022; 57(5):698-707. PubMed ID: 35172673
    [No Abstract]   [Full Text] [Related]  

  • 20. Challenges in implementing opioid agonist therapy in Lebanon: a qualitative study from a user's perspective.
    Ghaddar A; Khandaqji S; Abbass Z
    Subst Abuse Treat Prev Policy; 2018 Apr; 13(1):14. PubMed ID: 29673369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.